Expres2ion Biotech Holding Ab · OMXSTO:EXPRS2
Expres2ion Biotech Holding Ab — BioStock: Investing in Life Science 2025
13 slides from Expres2ion Biotech Holding Ab's conference presentation, Sep 23, 2025
Slide 1: ExpreS2ion Biotech - BioStock Investor Presentation
expreSceion BIOTE: Keith Alexander — CFO 23 September 2025 Hosted by STO: EXPRS2 n Biotech Holding AB
Slide 2: Disclaimer
expreScion BIOTECH Disclaimer This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise acquire, any shares or any other securities in ExpreS2ion Biotech Holding AB (the “Company"). Neither shall the presentati
Slide 3: Breast Cancer: The #1 Killer in Women's Health
expreSeion BIOTECH Breast Cancer: The #1 Killer in Women's Health Current drugs save lives but leave too many behind HER2 Expression * 2.3 million women diagnosed each year! — the most common cancer = globally — HER2 receptors * 685,000 annual deaths! — the leading cause of cancer mortality in send
Slide 4: Beyond Single Targets: Mobilizing the Full Immune Response
expreSeion Beyond Single Targets: Mobilizing the Full siovecn Immune Response @ Targets the entire HER2 extracellular (all 4 extra-cellular domains) relevantelial ExpreS2” platform (7) Triggers a polyclonal antibody response 7) Aims to break immune tolerance = 50 HER2 molecules) ©) ) Proven Virus-Li
Slide 5: Broad polyclonal immune response of ES2B-C001 over monoclonal antibodies
• • A further advantage of ES2B-C001 over monoclonal antibodies was the induction of a broad polyclonal immune response, comprising all IgG isotypes, including IgG2a, IgG2b and IgG3, which were previously found to be instrumental in the protection of transgenic mice from HER-2 expressing tumors [31,
Slide 6: From First Signals to Pharma Deal
From First Signals to Pharma Deal 2025 2026 2027 2028 2029 2030 2031 Phase I: First human data Phase Il: Proof of conceptin Breast Cancer Potential Phase || in Gastric Gameer tinsel Phase Ill: Pivotal/registration trial Possible conditional roval rtunity Target event expreSeion BIOTECH Phase | statu
Slide 7: Significant Market Opportunity
Significant Market Opportunity Patient distribution by region and cancer type! 1,000,000 800,000 | , on to additional act e 600,000 400,000 -— ° 200,000 . x = HER2+ BC HER2-low BC. HER2-ultra low BC HER2+ GC mChina Europe US mJapan mKorea mCanada m Australia (> } BC: Breast Cancer; GC: Gastric Cance
Slide 8: Big Pharma Bets Billions on HER2 Therapies
Big Pharma Bets Billions on HER2 Therapies Multi-billion dollar M&A and licensing deals show strong demand for innovative HER2 treatments Key transactions 2025 2023 2023 2021 2020 2020 2019-2021 2019 2018 2018 2015 2009 STX-478 ZN-A-1041 Mirvetuximab soravtansine Disitamab vedotin Tucatinib Ladiratu
Slide 9: Platform-Based Immunotherapy Company
expreSceion BIOTECH Platform-Based Immunotherapy Company Multiple shots on goal across cancer and infectious diseases, powered by ExpreS2® platform Target Pre-clinical DISEASE Project/Target ID Identification | Pharmacology | cGMP / Tox Phase | Phase I Phase Ill Collaboration Partner R Breast Cancer
Slide 10: Extensive Immunotherapy Development and Oncology Experience
Extensive Immunotherapy Development and —s**P'®5é28 Oncology Experience Executive Management Fully capable of executing to phase Il POC Bent U. Frandsen CEO 30 years life science management, . business development and finance BALK | | 4 KR] | rcconvoe MSc, Copenhagen Business School experience ” PhD
Slide 11: Funded Through Q1 2026
Funded Through Q1 2026 — exprescion Current Round Extends Runway Runway through Q1 2026 (excluding TO 11) Today (Q2 2025) ) (Near-Term 2025 Milestones Mid-/Late 2026 Milestones * Cash: SEK 49 million (Q2 2025) (Dec) + Phase 1a: Safety & maximum tolerated + TOT! warrant exercise + Immunology data (in
Slide 12: Summary (Why Invest)
expreSeion BIOTECH Summary (Why Invest) ¢ Large unmet medical need * Differentiated therapeutic approach ¢ Strong preclinical proof-of-concept * Catalysts ahead from clinical progress * Significant market & revenue potential ¢ Experienced team & partnerships ¢ Financially prudent with cash for near-
Slide 13: Q&A
expreSceion 5 BIOTECH Q&A EXPRS2 Innovative vaccines for a F investor@ expres2ionbio.com https://investor. expres2ionbio.com
ExpreS2ion Biotech Holding — BioStock: Investing in Life Science 2025 on 6ix